Comparing Revisional Laparoscopic Roux-en-Y Gastric Bypass Versus Ringed Revisional Roux-en-Y Gastric Bypass After Laparoscopic Sleeve Gastrectomy

Comorbidity resolution

T2DM (type 2 diabetes mellitus) Clinical Remission Criteria (T2DM) The American Diabetes Association (ADA) and other international experts define remission based on glycemic levels in the absence of glucose-lowering medications for at least 3 to 12 months. Complete Remission: HbA1c \< 5.7% and Fasting Plasma Glucose (FPG) \< 100 mg/dL. Partial Remission: HbA1c between 5.7% and 6.4% and FPG between 100-125 mg/dL. Improvement: A significant reduction in HbA1c (\>1%) or FPG (\>25 mg/dL), or a substantial decrease in medication dosage (e.g., stopping insulin) without meeting full remission criteria.

Time frame: 6 months, 1,2,3,4 and 5 years postoperatively

Comorbidity resolution

HTN (hypertension) Comparing pre- and postoperative results for hypertension (HTN) involves tracking clinical benchmarks that measure both blood pressure (BP) levels and the intensity of medical therapy required for control. Clinical Metrics for Comparison Blood Pressure Readings: Comparison of mean systolic and diastolic BP. Preoperative levels (typically around 140/90 mmHg) are compared against postoperative follow-up intervals. Medication Load: Tracking the total number of antihypertensive agents (AHMs). A common outcome is the likelihood of complete AHM discontinuation, which is significantly higher (around 32%) in surgical patients. Resolution vs. Improvement: Resolution: Often defined as achieving a BP \<140/90 mmHg (or \<130/80 mmHg per some AHA guidelines) while being off all medications. Improvement: Defined as a ≥30% reduction in antihypertensive medications while maintaining controlled BP.

Time frame: 6 months, 1,2,3,4 and 5 years postoperatively

Comorbidity resolution

OSA (obstructive sleep apnea) The most reliable way to compare status is through a follow-up polysomnography or home sleep test. Apnea-Hypopnea Index (AHI): This is the primary metric. It measures the number of pauses in breathing per hour of sleep. Cure/Resolution: Defined as an AHI \< 5. Improvement: Often defined as an AHI reduction of at least 50% or reaching a threshold of AHI \< 15. Oxygen Desaturation Index (ODI): Measures the number of times blood oxygen levels drop significantly per hour. Bariatric surgery typically leads to a marked decrease in this index. Mean and Nadir SpO2: Comparison of average and lowest oxygen saturation levels during sleep, which generally increase after surgery. Treatment Requirements CPAP Pressure: For patients who still require treatment, the required therapeutic pressure (measured in cmH2O or mbar) typically decreases post-operatively. Discontinuation Rate: A common comparison point is the percentage of patients who can stop using CPAP entirely.

Time frame: 6 months, 1,2,3,4 and 5 years postoperatively

Quality of Life (SF-36)

Quality of Life (QoL) scores typically show dramatic initial improvements, particularly in physical domains, followed by a stabilization or gradual decline over the long term. The Short Form-36 (SF-36) questionnaire measures eight health domains on a scale of 0 (lowest) to 100 (highest): Physical Component Summary (PCS): Includes Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), and General Health (GH). Mental Component Summary (MCS): Includes Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). Typical Score Trends Pre-Surgery (Baseline): Patients often start with global QoL scores around 45.6 to 48.3. Physical component scores are typically significantly lower than population norms. 1 Year Post-Surgery: Global scores often peak, reaching approximately 79.7. Both PCS and MCS frequently return to or exceed general population norms (typically around 50 for summary scores) during this period.

Time frame: 1, 2, 3, 4, and 5 years postoperatively

Food tolerance (FTQ)

Food tolerance is a key measure of success after bariatric surgery, often assessed using the Food Tolerance Quality (FTQ), also known as the Suter Score or "Quality of Alimentation" questionnaire. This standardized tool quantifies how well you can ingest and digest various foods without symptoms like nausea, vomiting, or pain. The FTQ evaluates three main areas to produce a score between 1 and 27: Satisfaction: Your overall perception of your eating quality (from "excellent" to "very bad"). Food Variety: Your ability to eat 8 specific food groups (red meat, white meat, fish, vegetables, salad, rice, pasta, and bread) without difficulty. Vomiting/Regurgitation: The frequency of these symptoms (scored 0-6). Scoring Breakdown: ≥24: Good food tolerance. 20-24: Moderate food tolerance. \<20: Poor food tolerance.

Time frame: 6 months, 3 and 5 years postoperatively.

Comorbidity resolution

Dyslipidemia Comparing pre-operative to post-operative lipid profiles involves monitoring specific biochemical markers and clinical milestones at standardized intervals. 1\. Key Biochemical Markers Clinicians track four primary components to measure improvement or resolution: Triglycerides (TG): Usually show the most rapid and significant drop post-surgery. HDL ("Good") Cholesterol: Typically starts low pre-operatively and increases significantly over 12-15 months. LDL ("Bad") Cholesterol: Often decreases, though the extent of change can vary depending on the surgical procedure. TC/HDL Ratio: This ratio is a key indicator of cardiovascular risk reduction. Clinical Definition of Resolution A patient is often considered to have "resolved" dyslipidemia if they meet these post-operative criteria without the use of lipid-lowering medications: LDL: \<160 mg/dL (or specific target based on risk). Triglycerides: \<200 mg/dL. HDL: \>40 mg/dL (men) or \>50 mg/dL (women).

Time frame: 6 months, 1,2,3,4 and 5 years postoperatively

Safety outcomes: Bleeding

General perioperative complications: Bleeding: Major postoperative bleeding (mPOB) in bariatric patients is generally defined by the following metrics: Hemoglobin Drop: A decrease in hemoglobin levels of more than 2 g/dL, often within 48 hours. Clinical Intervention: A requirement for transfusion (e.g., more than or equal 2 units of red blood cells), therapeutic endoscopy, or surgical re-intervention. Clinical Symptoms: Tachycardia (more than 120 bpm), hypotension (less than 90 over 60 mmHg), dizzy spells, or the presence of bloody drainage.

Time frame: perioperative until 1 month postoperatively

Safety outcomes: Anastomotic leak

General perioperative complications: Anastomotic leak: CT Scan with Oral/IV Contrast: Considered the most reliable imaging modality, though CT can sometimes fail to show minor leaks.

Time frame: perioperative until 1 month postoperatively

Safety outcomes: Infection

General perioperative complications: Infection: Measurement and Diagnostic Metrics C-Reactive Protein (CRP): A key, non-specific blood marker used to predict postoperative infections. Studies indicate that high CRP levels on post-operative days (PODs) 3 and 5 are indicative of infectious complications, particularly in differentiating between simple, low-risk cases and those with severe infection. White Blood Cell Count (WBC): Frequently monitored alongside CRP for signs of systemic inflammation.

Time frame: perioperative until 1 month postoperatively

Safety outcomes: DVT/PE

General perioperative complications: Deep vein thrombosis/Pulmonary embolism Measurement and Diagnostic Methods: Imaging (Gold Standard): Spiral CT angiography (PE protocol) is the definitive diagnostic method for pulmonary embolism. Venous Ultrasound: Used to detect lower extremity DVT, which can be suspected if there is \>3 cm difference in circumference between legs, or symptomatic swelling. Laboratory Tests: D-dimer tests are used to detect fibrin degradation, helping to rule out thrombosis.

Time frame: perioperative until 1 month postoperatively

Safety outcomes: Ring-related complications

Ring-related complications: Early: leak, hemorrhage, melena, vomiting, internal or port-site hernia. Late: slippage, erosion, stenosis, chronic vomiting, persistent food intolerance.

Time frame: At 1, 3, 4, and 5 years, or earlier if symptomatic (dysphagia, vomiting, suspected stricture, ulcer, or band-related complication).

Reoperation rates

The reoperation rates done in a number of patients between the 2 groups.

Time frame: 1, 2, 3, 4, and 5 years postoperatively

Operative data

operative time between the 2 groups (RYGB vs. B-RYGB)

Time frame: Intraoperative

Metabolic/hormonal panel

Clinical Significance Appetite Suppression: Elevated PYY promotes an early sense of satiety and reduced meal size, contributing to sustained weight loss. Diabetes Remission: PYY is a key humoral factor in the early recovery of impaired insulin and glucagon secretion after surgery, often independent of weight loss. Predicting Outcomes: The ability of PYY to increase early after surgery (measured 6 months post-op) is a strong predictor of long-term weight maintenance at 3 years. Common PYY Measurement Values Healthy circulating levels vary based on fasting state and sex: Fasting Levels: Typically range from 10 to 17 pmol/L in lean individuals. In mass units, average fasting levels are often around 100-120 pg/mL. Postprandial (After Meal) Peak: Levels usually rise within 1 hour of eating, typically reaching 23-45 pg/mL or higher depending on meal size and caloric density.

Time frame: 6months, 1,2,3 and 5 years postoperatively

Metabolic/hormonal panel

Measuring endogenous GLP-1 is challenging because it has a very short half-life of roughly 1-2 minutes before being degraded by enzymes. Fasting Levels: Typically range from 0 to 15 pmol/L. Post-Meal Levels: Can increase 2- to 3-fold following food consumption. Measurement Methods: Laboratory tests primarily use ELISA (Enzyme-Linked Immunosorbent Assay) to detect either "active" GLP-1 or "total" GLP-1. One of the primary reasons bariatric surgery is so effective for weight loss and type 2 diabetes remission is the dramatic natural increase in GLP-1 production after surgery. Postprandial (After-Meal) Levels: Following procedures like Roux-en-Y gastric bypass (RYGB), post-meal GLP-1 levels can increase by as much as 10-fold compared to pre-surgery levels. This happens because food reaches the distal part of the small intestine much faster than before. Weight Loss Marker: Higher post-surgical GLP-1 responses are often associated with more robust and sustained weight loss.

Time frame: 6months, 1,2,3 and 5 years postoperatively

Metabolic/hormonal panel

GIP (Gastric Inhibitory Polypeptide or Glucose-dependent Insulinotropic Polypeptide) measurements involve determining blood levels of this hormone, primarily for researching metabolism, obesity, and diabetes. Total GIP (active 1-42 + inactive 3-42) is measured using ELISA kits. RYGB typically leads to a decrease in GIP levels, particularly in response to food (postprandial). Mechanism: The "Foregut Hypothesis" suggests that bypassing the duodenum and proximal jejunum-where GIP-producing K-cells are most concentrated-prevents nutrients from stimulating these cells. Fasting Levels: Many studies show a significant decrease in fasting GIP levels within 1 to 6 months post-surgery. Postprandial Levels: Research consistently finds lower post-meal GIP concentrations compared to pre-operative levels. Clinical Impact: Lower GIP is associated with reduced fat accumulation and improved insulin sensitivity, contributing to the resolution of Type 2 Diabetes.

Time frame: 6months, 1,2,3 and 5 years postoperatively

Metabolic/hormonal panel

Leptin Bariatric surgery leads to significant decreases in fasting leptin levels, often reported as a decline from pre-operative obesity levels. Leptin is typically measured through blood tests using the following laboratory techniques: ELISA (Enzyme-Linked Immunosorbent Assay): The most common method used in clinical research to quantify serum or plasma leptin concentrations. Normal Ranges (Reference): Females: 0.5 to 15.2 ng/mL. Males: 0.5 to 12.5 ng/mL.

Time frame: 1,3 and 5 years postoperatively

Metabolic/hormonal panel

Ghrelin Measurement results are more heterogeneous. While some studies show a significant decrease in the first few months, others report that levels may return to or even exceed baseline at one year. Researchers and clinicians use several specialized techniques to measure ghrelin in bariatric patients: Assay Types: ELISA (Enzyme-Linked Immunosorbent Assay): The most common method for measuring total or acylated ghrelin in blood plasma or serum. Before surgery, ghrelin levels in obese individuals are typically lower than in lean individuals. Obese Baseline: Often ranges between 300-600 pg/mL for total ghrelin. Lean Reference: Generally higher, often exceeding 800 pg/mL.

Time frame: 1,3 and 5 years postoperatively